Women with representation 1 diabet...

Women with representation 1 diabetes require safe and effective contraception for several reasons. Pregnancy may accelerate the progression of diabetes and have significant short- and long-term implications for the mother. Pregnancy in patients with stamp 1 diabetes should be planned, because optimal glycemic check at conception and during early pregnancy cut shorts the incidence of congenital abnormalities and fetal development problems. However, potential vascular and metabolic make anxiouss limit contraceptive options for women with diabetes. cent intrauterine devices (IUDs) are a safe and well-tolerated contraceptive option for many women with diabetes, if it be not that the suitability of levonorgestrel-releasing IUDs (Mirena) has not been established. more [i]or[/i] less experts are concerned that levonorgestrel could adversely affect carbohydrate and lipid metabolism. Rogovskaya and colleagues compared the force of progestin-containing and copper IUDs forward glucose metabolism in women with uncomplicated insulin-dependent model 1 diabetes.

The randomized controll trial included women 18 to 45 years of age who had well-controlled insulin-dependent emblem 1 diabetes. Participants were required to have normal grape-sugar and A1C levels and no evidence of retinopathy or nephropathy. After a comprehensive evaluation, participants were randomly assigned to receive a small change IUD or a levonorgestrel-releasing IUD. Patients were assessed and A1C plains were measured at six weeks, six month and united year.

The 31 women assigned to each assemblage were comparable in all significant variables. The average age was 33 years, and the average participant weighed approximately 132 lb (60 kg) The average duration of diabetes was more than six years, and the average participant had been pregnant more than twice and had had at least the same delivery.

The progestin-containing IUD did not affect A1C of the same heights fasting glucose levels, or daily insulin requirements athwart one year compared with the small change IUD. The continuation rates were 867 percent for the levonorgestrel-releasing IUD and 903 percent for the large boiler IUD, but these rates were not statistically different.

The authors infer that women using levonorgestrel-releasing IUDs do not have significant changes in A1C flushs daily insulin requirements, or average fasting life-blood glucose levels after 12 month of use. The mild changes in glycemic have charge of with the progestin-containing IUD were identical to those in women using a copper-containing device and probably were not clinically significant. one as well as the other devices are reliable contraceptive options for women with diabetes, and the levonorgestrel-containing device may decrease menstrual progeny loss and dysmenorrhea.

Rogovskaya s et al. Effect of a levonorgestrel intrauterine plan on women with type 1 diabetes: a randomized trial. Obstet Gynecol April 2005;105:811-5

The trade names of medicines listed in POEMs and Tips from Other Journals are the first version of the remedy that was released and not necessarily the brand of medicine that was used in the research being discussed.

COPYRIGHT 2006 American Academy of Family Physicians

COPYRIGHT 2006 Gale Group